Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07141199 · ClinicalTrials.gov registry record · Phase 1

A Study to Evaluate Adverse Events, How the Drug is Tolerated, and How the Drug Moves Through the Body of Intravenous Infusions of ABBV-8736 in Adult Healthy Volunteers

A Phase 1 study of Healthy Volunteer, sponsored by AbbVie.

Active
Registry status
Phase 1
Development phase
24
Enrollment target
1
Study location

NCT07141199: Active Phase 1 study of Healthy Volunteer, sponsored by AbbVie.

NCT07141199 is a Phase 1 study of Healthy Volunteer that is active but no longer recruiting, run by AbbVie. The registered enrollment target is 24 participants, below the 202-participant average among 112 other Healthy Volunteer trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07141199, a Phase 1 study of Healthy Volunteer, is active but no longer recruiting, sponsored by AbbVie.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
24 participants
Enrollment target
1
Study location

Study Summary

The objective of this study is to assess the safety, tolerability, pharmacokinetics, and immunogenicity following multiple intravenous (IV) ascending doses of ABBV-8736 in healthy adult participants.

Primary Outcome

An AE is defined as any untoward medical occurrence in a patient or clinical investigation in which a participant is administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG ABBV-8736

Study Locations (1)

Illinois

  • Acpru /Id# 277377 - Grayslake

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2025-09-02
Est. Completion 2026-04
Phase Phase 1
AbbVie

526 total trials

What the registry record for NCT07141199 still lists

NCT07141199 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 202-participant average among 112 other Healthy Volunteer trials with a reported enrollment target (88% lower).

The record links to 1 condition, with Healthy Volunteer appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT07141199 reports a single indexed study location in Illinois.

Frequently Asked Questions

What is clinical trial NCT07141199 about?

NCT07141199 is a clinical study titled "A Study to Evaluate Adverse Events, How the Drug is Tolerated, and How the Drug Moves Through the Body of Intravenous Infusions of ABBV-8736 in Adult Healthy Volunteers". The objective of this study is to assess the safety, tolerability, pharmacokinetics, and immunogenicity following multiple intravenous (IV) ascending doses of ABBV-8736 in healthy adult participants.

What is the current status of trial NCT07141199?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2025-09-02. Estimated completion is 2026-04.

What conditions does trial NCT07141199 study?

This clinical trial studies the following conditions: Healthy Volunteer.

What interventions are being tested in trial NCT07141199?

The interventions under investigation include: Placebo (DRUG), ABBV-8736 (DRUG).

Who is sponsoring clinical trial NCT07141199?

This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07141199 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Volunteer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07141199's enrollment target sits among peer trials

24 85th of 112 higher than 20 of 112 other Healthy Volunteer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy Volunteer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02331979 · 24 participants · NA

    Improving Bladder Function in SCI by Neuromodulation

  • NCT03096197 · 24 participants · NA

    Exoskeleton and Spinal Cord Stimulation for SCI

  • NCT03223922 · 24 participants · NA

    Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases

  • NCT03326921 · 24 participants · Phase 1

    HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07141199, the US trial registry maintained by the National Library of Medicine. NCT07141199 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.